Metabolic modes of action of the statins in the hyperlipoproteinemias.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Atherosclerosis

• Publication date

  1998-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0021-9150(98)00198-1PMID 9862169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

  2004cited by this paper
• Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.

  2004cited by this paper
• Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats.

  1997cited by this paper
• A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.

  1997cited by this paper
• 1.P.178 Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia

  1997cited by this paper
• Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

  1997cited by this paper
• Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

  1997cited by this paper
• Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.

  1997cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

  1997cited by this paper
• Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

  1997cited by this paper
• Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man.

  1997cited by this paper
• Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.

  1997cited by this paper
• ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools.

  1996cited by this paper
• Design and analysis of lipid tracer kinetic studies

  1996cited by this paper
• Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

  1996cited by this paper
• Role of cholesterol in regulating apolipoprotein B secretion by the liver.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

  1995cited by this paper
• Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

  1994cited by this paper
• Effects of simvastatin on apoB metabolism and LDL subfraction distribution.

  1993cited by this paper
• Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia

  1993cited by this paper
• The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia

  1993cited by this paper
• Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.

  1993cited by this paper
• Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.

  1992cited by this paper
• The discovery and development of HMG-CoA reductase inhibitors.

  1992cited by this paper
• Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes.

  1991cited by this paper
• Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia

  1991cited by this paper
• Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.

  1991cited by this paper
• Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

  1990cited by this paper
• Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge.

  1990cited by this paper
• Cholesterol is required for secretion of very-low-density lipoprotein by rat liver.

  1989cited by this paper
• Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.

  1989cited by this paper
• Regional specificities of monoclonal anti-human apolipoprotein B antibodies.

  1988cited by this paper
• Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover.

  1988cited by this paper
• Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.

  1988cited by this paper
• Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

  1987cited by this paper
• Specific pools of phospholipids are used for lipoprotein secretion by cultured rat hepatocytes.

  1986cited by this paper
• Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.

  1985cited by this paper
• Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts.

  1983cited by this paper
• Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

  1981cited by this paper
• Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase.

  1978cited by this paper
• Receptor-mediated control of cholesterol metabolism.

  1976cited by this paper
• Lipoprotein receptors, cholesterol metabolism, and atherosclerosis.

  1975cited by this paper
• Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins.

  1973cited by this paper

• The comorbidity burden of diabetes and stroke: a retrospective study in Beijing, China

  2025cites this paper
• Hypertriglyceridemic hyperapoB and the development and resolution of nonalcoholic fatty liver disease: a cohort study

  2023cites this paper
• Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration

  2022cites this paper
• Postoperative Cardiac Surgery Outcomes in a Statin-Native Population

  2018cites this paper
• Nanoemulsified gamma-oryzanol rich fraction blend regulates hepatic cholesterol metabolism and cardiovascular disease risk in hypercholesterolaemic rats

  2016cites this paper
• Cu-Catalyzed ligand-free synthesis of rosuvastatin based novel indole derivatives as potential anticancer agents

  2016cites this paper
• Lipid-Lowering Agents

  2015cites this paper
• A Comparative Study of Efficacy and Safety of Pitavastatin and Atorvastatin in Dyslipidemic Patients

  2015cites this paper
• Atorvastatin prevents type 2 diabetes mellitus--an experimental study.

  2014cites this paper
• Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin.

  2014cites this paper
• Patogenetyczne uzasadnienie stosowania statyn w profilaktyce udaru niedokrwiennego mózgu w świetle zapalnej teorii rozwoju miażdżycy

  2012cites this paper
• Remnant Lipoproteins are a Stronger Risk Factor for Cardiovascular Events than LDL-C - From the Studies of Autopsies in Sudden Cardiac Death Cases

  2012cites this paper
• [Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis].

  2012cites this paper
• Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression.

  2012cites this paper
• Utilization Pattern of Statins in an Indian Population.

  2012cites this paper
• Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.

  2011cites this paper
• Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle

  2011cites this paper
• PERFIL DOS USUÁRIOS DO HIPOLIPEMIANTE ATORVASTATINA (Tipo: Artigo)

  2010cites this paper
• Perioperative statin use: an update.

  2010cites this paper
• Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment.

  2010cites this paper
• Beneficial effects of combined administration of sodium molybdate with atorvastatin in hyperlipidemic hamsters.

  2009cites this paper
• Simvastatin Induces Apoptosis of Fibroblast-Like Synoviocytes

  2009cites this paper
• cotoxicological aspects related to the presence of pharmaceuticals in the quatic environment

  2009cites this paper
• Drug Discoveries & Therapeutics

  2008cites this paper
• UNIVERSIDADE DE SÃO PAULO FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Fármaco e Medicamentos Área de Produção e Controle Farmacêuticos

  2008cites this paper
• Étude des mécanismes athérogènes associés à l'insulino-résistance et l'hypercholestérolémie familiale

  2008cites this paper
• A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.

  2007cites this paper
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.

  2007cites this paper
• Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.

  2007cites this paper
• Studies on lipoprotein kinetics in obesity and the metabolic syndrome: impact of dietary weight loss and statin therapy

  2007cites this paper
• Propuesta para la vicepresidencia de la Sociedad Mexicana de Nutrición y Endocrinología (2008)

  2007cites this paper
• The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus Published, JLR Papers in Press, October 28, 2005.

  2006cites this paper
• Lipoprotenas clsicas, teraputicas modernas. Farmacologa de las lipoprotenas de alta densidad

  2006cites this paper
• [Atherosclerosis plaque regression].

  2006cites this paper
• Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice

  2005cites this paper
• Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: Effects of simvastatin

  2005cites this paper
• Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues.

  2005cites this paper
• ATORVASTATIN: EFFICACY IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE WITH EMPHASIS TO ATHEROGENESIS

  2005cites this paper
• [The interest of statins in nephrology].

  2004cites this paper
• Dyslipidemia in Visceral Obesity

  2004cites this paper
• Chapter 1 – History and Biochemistry of Statins

  2004cites this paper
• Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

  2004cites this paper
• CONTRIBUTION DE LA PROTÉINE DE TRANSFERT DES ESTERS DE CHOLESTÉROL À L'HÉTÉROGÉNÉITÉ DES PARTICULES LDL DANS L'HYPERCHOLESTÉROLÉMIE FAMILIALE HÉTÉROZYGOTE

  2004cites this paper
• Lipid disturbances in chronic renal failure--patomechanisms and treatment.

  2004cites this paper
• Lipid-Lowering Responses Modified by Genetic Variation

  2004cites this paper
• Dyslipidemia in the metabolic syndrome

  2004cites this paper
• Intérêt des statines en néphrologie

  2004cites this paper
• Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.

  2003cites this paper
• Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes

  2003influential citation
• Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy

  2003cites this paper
• Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

  2003cites this paper
• Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds.

  2002cites this paper
• Effect of Simvastatin on markers of triglyceride‐rich lipoproteins in familial hypercholesterolaemia

  2002cites this paper
• Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

  2002cites this paper
• Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.

  2002cites this paper
• Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation.

  2002cites this paper
• Hiperlipidemia familiar combinada: caracterización en población mexicana

  2002cites this paper
• Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.

  2002cites this paper
• Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

  2002cites this paper
• Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.

  2002cites this paper
• Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies

  2002cites this paper
• The Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus Infection

  2001cites this paper
• Lipid-lowering drugs in lupus: an unexplored therapeutic intervention

  2001cites this paper
• SCAP ligands are potent new lipid-lowering drugs

  2001cites this paper
• Effects of omega-3 fatty acids on blood lipids and endothelial function in hyperlipidemic patients treated with statins

  2001cites this paper
• [Familial hypercholesterolemia].

  2001cites this paper
• Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus

  2001cites this paper
• Is a statin a statin?

  2001cites this paper
• Evidence of Dyslipidemia and CVD in HIV Infection

  2001cites this paper
• High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.

  2000cites this paper
• Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?

  2000cites this paper
• SIALIC ACID IN LIPOPROTEINS WITH A SPECIAL REFERENCE TO LOW DENSITY LIPOPROTEINS

  2000cites this paper
• Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

  2000cites this paper
• Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm.

  2000cites this paper
• Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease.

  2000cites this paper
• The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.

  1999cites this paper
• [The hyperlipidemias. Role of various statins].

  1999cites this paper
• Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs.

  1999cites this paper
• The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs1.

  1999cites this paper
• Lipid disturbances in chronic renal failure – patomechanisms and

  year unknowncites this paper